Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Valeant Pharmaceuticals International ( VRX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.8%. By the end of trading, Valeant Pharmaceuticals International fell $1.13 (-1.1%) to $100.20 on light volume. Throughout the day, 958,879 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,490,500 shares. The stock ranged in price between $99.97-$101.74 after having opened the day at $101.50 as compared to the previous trading day's close of $101.33. Other companies within the Drugs industry that declined today were: Neurocrine Biosciences ( NBIX), down 29.7%, Chemocentryx ( CCXI), down 24.3%, Peregrine Pharmaceuticals ( PPHM), down 6.6% and Genvec ( GNVC), down 6.2%.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $33.3 billion and is part of the health care sector. Shares are up 67.7% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and generally higher debt management risk.

On the positive front, NanoString Technologies ( NSTG), up 70.6%, GW Pharmaceuticals PLC ADR ( GWPH), up 53.9%, XenoPort ( XNPT), up 17.1% and Galectin Therapeutics ( GALT), up 15.3% , were all gainers within the drugs industry with Johnson & Johnson ( JNJ) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.